SCHEMBL15070437

SCHEMBL15070437

Cc1nc2ccc(NC(=O)N3CCOCC3)cc2s1

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 11/20 0.78
▸ RAB9A P51151 5/20 0.78
▸ HSD17B10 Q99714 4/20 0.78
▸ TSHR P16473 3/20 0.77
▸ ALDH1A1 P00352 7/20 0.71
▸ MAPT P10636 6/20 0.71
▸ KDM4E B2RXH2 5/20 0.71
▸ MEN1 O00255 2/20 0.71
▸ KMT2A Q03164 2/20 0.71
▸ POLB P06746 1/20 0.64
▸ LMNA P02545 3/20 0.62
▸ HPGD P15428 3/20 0.62
▸ LDHA P00338 2/20 0.61
▸ HTT P42858 2/20 0.57
▸ USP2 O75604 1/20 0.55
▸ GAA P10253 1/20 0.55
▸ CASP1 P29466 1/20 0.55
▸ CASP7 P55210 1/20 0.55
▸ NPC1 O15118 4/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10049918 0.79 HPGD (0.75) SMN1; SMN2HSD17B10TSHRALDH1A1MAPT
SCHEMBL4664159 0.78 LDHA (0.80) SMN1; SMN2RAB9AHSD17B10TSHRALDH1A1
SCHEMBL1745263 0.77 SMN1; SMN2 (0.56) SMN1; SMN2RAB9AHSD17B10TSHRALDH1A1
SCHEMBL1745541 0.77 SMN1; SMN2 (0.56) SMN1; SMN2RAB9AHSD17B10TSHRALDH1A1
SCHEMBL1745260 0.77 SMN1; SMN2 (0.56) SMN1; SMN2RAB9AHSD17B10TSHRALDH1A1
SCHEMBL3923955 0.76 LDHA (1.00) SMN1; SMN2RAB9AHSD17B10TSHRALDH1A1
SCHEMBL470957 0.75 HPGD (0.62) SMN1; SMN2HSD17B10TSHRALDH1A1KDM4E
SCHEMBL15195866 0.75 LDHA (0.76) SMN1; SMN2RAB9AHSD17B10TSHRALDH1A1
SCHEMBL458775 0.75 SMN1; SMN2 (0.57) SMN1; SMN2RAB9AHSD17B10TSHRALDH1A1
SCHEMBL31428688 0.74 RAB9A (0.55) SMN1; SMN2RAB9AALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181183-B2 Prostaglandin D synthase inhibitory piperidine compounds TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-11-10 — — US disclosed
US-9181183-B2 Prostaglandin D synthase inhibitory piperidine compounds TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-11-10 — — US disclosed
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-06-27 — — US disclosed
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS PTGIS, PTGS1, PTGDR SMN1; SMN2 4361/4885RAB9A 3049/4885HSD17B10 945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback